PL-0264
- Generic Name
- PL-0264
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 120
- Registration Number
- NCT06161519
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 44
- Registration Number
- NCT06162351
- Locations
- 🇫🇷
Institut Curie, Saint Cloud, France
PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers
Phase 1
Completed
- Conditions
- Small Cell Lung CancerExtra-Pulmonary Small Cell Carcinomas
- Interventions
- First Posted Date
- 2019-12-24
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 10
- Registration Number
- NCT04209595
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Phase I Study of PLX038 in Patients With Advanced Solid Tumors
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- ProLynx LLC
- Target Recruit Count
- 40
- Registration Number
- NCT02646852
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath